Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study

Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study

Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal function and proteinuria in real life have not yet be...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Patricia Muñoz Ramos, Yohana Gil Giraldo, Vicente Álvarez-Chiva, David Arroyo, Cristina Sango Merino, Francesc Moncho Francés, Javier Ocaña, Javier Reque, Emilio Sánchez-Álvarez, José Luis Górriz, Borja Quiroga
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
CKD
kidney function
PCSK9i
proteinuria
Microbiology
QR1-502
Accès en ligne:https://doaj.org/article/75a018c902c14923a7af7257c93f444c
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/75a018c902c14923a7af7257c93f444c

Documents similaires